Baird Raises Danaher (DHR) Price Target to $254
Key Points
- Baird maintained its Outperform rating on Danaher Corporation on October 22, 2026, while raising its price target to $254 from $246.
- Baird's $254 price target implies 8.89% upside from Danaher Corporation's ($DHR) current $233.27 share price.
- Danaher recently traded around $234.02, sitting below Baird's new price target of $254.
- Capital International Investors held a large stake of 15,504,420 shares worth about $3.63 billion in the company.
Get Danaher text alerts
We text you when insiders, Congress, analysts or big funds move on $DHR.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Danaher Corporation alert may contain errors. Disclosures
Baird reaffirmed its positive view on Danaher Corporation (NYSE: DHR) on October 22, 2026, keeping an Outperform rating while lifting its price target to $254 from $246. Research notes of this kind lay out a firm's forward-looking take on where a company's shares are headed over the intermediate term. Danaher closed at $233.86 on October 21, 2026.
DHR
Danaher Corporation
Baird vs. the S&P 500
Hypothetical returns from Baird's disclosed trades, not real profit or advice. How we model this.
Baird's Call on Danaher Corporation
Baird's decision to lift its target gives the stock more room in the eyes of the firm, moving from a previous target of $246 to $254 while retaining an Outperform rating. Analyst price targets represent a 12-month view on valuation, though market prices shift daily based on broader conditions.
Other Institutional Activity in Danaher Corporation
Capital International Investors grew its holdings by 1,489,759 shares, ending with 15,504,420 shares worth about $3,625,863,670 as of June 30, 2026, marking a 10.6% increase in its position.
Danaher Corporation Stock Up 4.0%
Danaher recently traded around $234.02 as of October 22, 2026, which is about equal to its prior close of $233.86. The stock trades above both its 50-day moving average of $215.12 and its 200-day moving average of $201.26, while sitting 3.6% below its 52-week high of $242.80.
$DHR price target
Danaher Corporation daily closes and this analyst's $254 target. Not advice.
Recent Earnings
Danaher reported trailing-twelve-month revenue of $25.11 billion alongside basic earnings of $6.04 per share. The healthcare products maker generated a net profit margin of 15.9% and a return on equity of 7.6%.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
5 target cuts vs 1 raises.
-
EPS & revenue
EPS beat estimates by 5.3%. Revenue missed estimates by 1.8%.
-
Profit surprise
EBITDA missed by 22 percent. Operating income missed by 23 percent.
-
Pre-earnings setup
Bar was high, analysts already very bullish.
-
Analyst signal
1 target raise, 5 target cuts.
-
Earnings quality
Gross margin down 1.1 points. Positive free cash flow.
Earnings Call Summary
Danaher started 2026 solidly with adjusted earnings per share of $2.06, up 9.5 percent year over year, beating the consensus of $1.95. Revenue came in at $5.951 billion, slightly below the $6.057 billion expected, due mainly to a lighter respiratory season at Cepheid being down roughly 25 percent. However, strong bioprocessing momentum, with consumables up high single digits and equipment orders surging over 30 percent year over year for the first time in nearly two years, offset weakness. Diagnostics and Life Sciences showed pockets of improvement, with Beckman Coulter diagnostics growing mid single digits outside China and newer products like the Xpert GI panel gaining traction.
Guidance Management raised full year adjusted earnings per share to $8.35 to $8.55 from the prior range. Revenue guidance remains 3 percent to 6 percent growth for the full year, with lower respiratory sales of $1.6 billion to $1.7 billion offset by better core growth elsewhere. Second quarter expected to show low single digit core revenue growth with operating margins around 26.5 percent.
Severe negative reset. The report materially damaged the forward outlook and likely forces major downward revisions.
Dividend
Danaher pays an annual dividend rate of $1.60 per share, giving it a dividend yield of 0.71% based on a payout ratio of 25.7%.
Insider Buying and Selling at Danaher Corporation
Insider transactions included Alan G. Spoon, Director, selling 1,358 shares on May 1, 2026, at an average price of $174.67 for a total value of $237,207. Later, Rainer M. Blair, Chief Executive Officer, sold 58,255 shares on August 21, 2026, valued at $12,736,095.
Analysts Set New Price Targets
Other Wall Street firms have also updated their views on Danaher in recent weeks. On October 5, 2026, RBC Capital maintained an Outperform rating and raised its target from $215 to $250. Barclays maintained an Overweight rating on October 7, 2026, lifting its target to $255 from $230. Morgan Stanley maintained an Overweight rating on October 13, 2026, with a target of $240. On the same day, TD Cowen maintained a Buy rating and raised its target to $255 from $236. Overall, the stock carries a consensus recommendation of strong buy from 22 analysts, with a mean price target of $247.18.
About Danaher Corporation
Danaher Corporation operates as a science and technology innovator that designs and manufactures professional, medical, and industrial products. The firm focuses on biotechnology, life sciences, and diagnostics segments, supplying tools and consumables used in research and clinical testing worldwide.
Bottom Line
Investors tracking Danaher will want to watch how shares perform relative to Baird's $254 target and monitor upcoming earnings reports for updates on revenue growth across its core segments.
Related Filing Alerts
Source: Baird's rating change on $DHR (Oct 22, 2026). Written by software, not financial advice. How we make alerts